We were delighted to discuss with Kim Papp (Probity Medical Research, Waterloo, ON, Canada) the results of the phase IIb study assessing the efficacy, safety and tolerability of sonelokinab (M1095), and IL-17 A/F nanobody, in patients with moderate-to-severe chronic plaques psoriasis (Clinical Trial Identifier: NCT03384745)
- What are the major unmet needs in the treatment of chronic plaque-type psoriasis? (0:22)
- Could you tell us a little about sonelokinab and its mechanism of action? (1:29)
- What were the aims, design and inclusion criteria of the Phase IIb study? (2:58)
- What have we learned from the efficacy and safety findings of the study? (5:13)
- What will be the next steps in the clinical development of sonelokinab in this indication? (7:54)
Disclosures: Kim Papp as acted as an advisor/speaker/consultant/steering committee member/researcher for AbbVie, Akros, Allergan, Amgen, Anacor, Arcutis, Astellas, AstraZeneca, Bausch Health (Valeant), Baxalta, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite, Celgene, Coherus, Dermira, Dow, Forward Pharma, Galderma, Genentech, Gilead, GlaxoSmithKline, InflaRx, Janssen, Kyowa Kirin, LEO Pharma, Lilly, MedImmune, Meiji Seika Pharma, Merck, Mitsubishi Tanabe Pharma, Moberg Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, and UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed as highlights of the 29th EADV Virtual Congress 2020.
Share this Video
Related Videos In Psoriasis
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Linda Stein Gold, EADV 2022: Quality of Life and Clinical Efficacy Findings from PSOARING 1 and PSOARING 2
PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) were two phase 3 trials investigating tapinarof cream, a novel, steroid-free, AhR modulating agent for the treatment of plaque psoriasis. It was a pleasure to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) around the aims, design, endpoints and quality of life and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!